GOVXNasdaqPharmaceutical PreparationsFiscal year ends December 31
GeoVax Labs, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 27, 2026
$0.23−0.01 (-4.53%)
Close on Oct 19, 2026
- Market cap
- $1.04M
- P/E (TTM)
- –
- Dividend yield
- –
GeoVax Labs, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q1 22 | Q4 21 | Q3 21 | Q2 21 | Q1 21 | Q4 20 | Q3 20 | Q2 20 | Q1 20 | Q4 19 | Q3 19 | Q2 19 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NIAID Grant [Member] | $81.53K | – | – | – | $110.42K | – | – | – | – | – | – | – | 100.0% | -26.2% |
| NIH Grants [Member] | – | $164.96K | $30.41K | $79.71K | $110.42K | $251.62K | $231.33K | $301.49K | $654.02K | $229.66K | $214.77K | $184.94K | – | – |
| Research Agreements [Member] | – | – | – | – | – | $0 | $184.13K | $139.11K | $61.96K | $38.85K | $118.44K | $25.00K | – | – |
| Leidos, Inc. Research Collaborative Agreement [Member] | – | – | – | – | – | – | $184.13K | $139.11K | $61.96K | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of GeoVax Labs's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.